

1 August 2024

## Important Information: Q-VAX® Vaccine (10041788) & Q-VAX® Skin Test (10040156) (inactivated *Coxiella burnetii*)

Dear Australian Veterinary Association,

I am writing on behalf of CSL Seqirus, manufacturer of Q-vax® Vaccine and Skin Test.

As a key industry stakeholder, I wanted to inform you that Q-vax® is listed as a current supply shortage on the Therapeutic Goods Administration (TGA) Medicines Shortage Database. We currently have stock on hand and are closely managing supply to ensure that it is available for Australians at highest risk of exposure, such as farmers, meat industry workers and veterinarians.

CSL Seqirus has put a plan in place to help maintain access to Q fever vaccines while we work to build up further supplies. This plan includes close collaboration with the TGA, vaccinating clinics and workplaces to ensure available stock is prioritised for those at highest risk.

We are working with frontline vaccinators to:

- Delay non-essential vaccinations.
- Minimise bulk ordering so that there isn't unused stock in clinics.
- Maximise the use of the skin test by forward planning patient appointments.

We know Q fever vaccination is part of inducting new veterinary students. Our management plan aims to ensure that stock is distributed centrally and available to those that are at high-risk of exposure, such as veterinarians and vet students. We are also aware that calving seasons can result in peaks in demand and have placed the vaccine on constrained supply in advance to help manage this demand as best as possible.

CSL Seqirus is working closely with wholesalers to identify specific customer needs. Please speak with your relevant wholesaler/healthcare professional as to your occupational health vaccine requirements. I would be happy to discuss further if you have any questions.

Kind Regards,



**Dr Matt Wenham**

Senior Manager – Stakeholder Engagement  
Biosecurity & Products of National Significance  
CSL Seqirus

If you do not wish to receive further information about any CSL Seqirus products and services, please email [SeqirusAU.SalesSupport@seqirus.com](mailto:SeqirusAU.SalesSupport@seqirus.com) or provide your fax number here: \_\_\_\_\_ and fax back to (03) 9389 2030.  
Before prescribing, please review the Product Information at [www.cslseqirus.com.au/products](http://www.cslseqirus.com.au/products). CSL Seqirus Medical Information: 1800 642 865.

Driven by **Our Promise™**

Seqirus (Australia) Pty. Melbourne ABN 66 120 398 067 Q-Vax® is a registered trademark and CSL Seqirus is a trademark of Seqirus UK Limited or its affiliates AU-QVAX-24-0008